writing and submitting an animal use protocol understanding the process

44
Writing and Submitting an Animal Use Protocol Understanding the Process http://tulane.edu/asvpr/iacu c/

Upload: laura-black

Post on 29-Dec-2015

219 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Writing and Submitting an Animal Use Protocol Understanding the Process

Writing and Submitting an Animal Use Protocol

Understanding the Process

http://tulane.edu/asvpr/iacuc/

Page 2: Writing and Submitting an Animal Use Protocol Understanding the Process

The charge of an Institutional Animal Care

and Use Committee (IACUC) as mandated by

NIH’s Office of Laboratory Animal Welfare

and the USDA is to

ensure the humane care for the use of animals

used in research and

compliance with guidelines and regulations.

Page 3: Writing and Submitting an Animal Use Protocol Understanding the Process

Protocol BreakdownEach section of the

protocol form will be

explained by

stating what information

is expected and

examples of

acceptable responses.

Page 4: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION I. RENEWAL PROTOCOLS

The committee is asking for a brief summary of what has been accomplished in the previous

3 years.

Information needed:•State what aims or experiments have been completed •Give a summary of outcomes•List publications that may have resulted

Page 5: Writing and Submitting an Animal Use Protocol Understanding the Process

Renewal summary example

Our studies to date have focused on the molecular mechanisms that underlie dendrite development, with emphasis on the AMPA glutamate receptor signaling pathway. Since the morphology of neuronal dendrites is a key determinant of the firing patterns of the neuron, and hence neural network properties, the ability of AMPA receptor expression to alter dendrite morphology may have critical implications for firing patterns of brain networks as a whole.  Our studies demonstrated that expression of AMPA glutamate receptor subunits controls dendrite morphology but in a subunit- and region-specific manner. For example, in motor neurons, expression of the GluR1 subunit promotes outgrowth of new dendritic branches, whereas expression of GluR2 promotes elongation of existing branches (Prithviraj et al., 2008). In the cortex, expression of either GluR1 or GluR2 promotes addition of new branch segments (Chen et al., 2009), suggesting that there are region-specific cellular mechanisms that link glutamate receptors to dendrite branch formation. We also found that the effects of AMPA receptors on dendrite morphogenesis are distinct from those of other glutamate receptors (Prithviraj and Inglis, 2008), suggesting distinct roles for specific glutamate receptor subunits in the developmental regulation of neuronal dendrite outgrowth.  Publications arising from work covered by the previous protocol:Prithviraj R., Kelly K.M., Clarke A., Hexom T., Espinoza-Lewis R., Inglis, F.M. (2008) Differential regulation of dendrite morphogenesis by AMPA receptor subunits GluR1 and GluR2 in motor neurons. Developmental Neurobiology, 68:247-64. Prithviraj R., Inglis, F.M. (2008) Expression of the motor neuron specific NMDA receptor subunit NR3B regulates dendrite morphogenesis in spinal motor neurons. Neuroscience, 155:145-53.

Page 6: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION III. SPECIES, NUMBER & CATEGORY OF ANIMAL USE

1. List the SPECIES2. List the STRAIN3. List the NUMBER4. USDA CATEGORY:• B - animals held, conditioned or bred. No procedures conducted• C – teaching or research involving no pain, distress or use of

analgesia• D – teaching or research involving pain or distress accompanied

with appropriate use of analgesia, anesthetic• E - teaching or research involving pain or distress for which the

appropriate use of analgesia, anesthetic will alter the results of the experiment. The justification for not using appropriate anesthetic, analgesic or tranquilizing drugs must be provided.

Page 7: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION IV. REGULATORY INFORMATION

1. Is this an endangered or threatened species?    2. Is short‑term (> 30 minutes; < 12 hours) physical restraint of a conscious animal employed?

     3. Is long‑term (12 hours or more) physical restraint of a conscious animal employed?

4. Will specialized management procedures be required, e.g. specialized caging equipment, restricted or altered feeding/watering/sanitization schedules, or environmental parameters such as cage size, temperature, lighting or other fall outside the “Guide for the Care and Use of Laboratory Animals”?

Information needed: This is the most common one answered. Examples of specialized management procedures would be using mice that need sterile setups, metabolic cages for urine collection, drugs given in food or water.

Example Response: Athymic nude mice require sterile housing and autoclaved food and water due to their immunocompromised status.

5. Will you perform more than one major survival surgery on any animal? PLEASE NOTE: major survival surgery penetrates and exposes a body cavity or produces substantial impairment of physical or physiologic functions (such as laparotomy, thoracotomy, craniotomy, joint replacement or limb amputation)

6. Will animals be housed outside of AAALAC-accredited Tulane facilities for over 12 consecutive hours? If YES, the proposed site must be inspected and approved by the IACUC prior to use. Please list the location with justification below.

Page 8: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION IV. REGULATORY INFORMATION

7. Will pain or distress without the use of analgesic or anesthetic agents occur during the course of experimentation? This is Category E and must be scientifically justified with references.

Example Response: The proposed experiments necessitate the full manifestation of bacterial infection in the selected animals in order to fully characterize the health effects of the disease. The use of analgesics during the course of the study to alleviate pain might modify the host’s response to infectious challenge that could compromise the results of the study. Narcotic analgesics can cause respiratory depression (Butelman et al., 1995) and stimulate the production of a number of immunomodulatory effects laboratory animals. In-vitro exposure of murine lymphocytes and macrophages to morphine and its metabolites at a wide range of concentrations resulted in suppressed B cell proliferation, suppression of IL-2, IL-4, and IL-6, and inhibited cytotoxic T-lymphocyte induction (Thomas et al., 1995). In addition, opioid analgesics also have immunomodulatory attributes in mice. Opioids have shown a dose dependent attenuation of the serum TNF-a response in mice as a result of exposure to LPS and results in a significantly lower LPS-induced serum TNF-aincrease (Piersma et al., 1999). Opoid analgesics also suppress T- and B-cells, depress NK activity, and decrease the primary antibody response. Steroidal and nonsteroidal anti-inflammatories interfere with the inflammatory pathway, which is critical in the pathogenesis of the infectious disease process.

Butelman ER, Winger G, Zernig G, Woods JH. Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys. J Pharmacol Exp Ther 1995;272:845-53.

8. Will these procedures be filmed, videotaped or photographed for use outside the institution?      

Page 9: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION V. PERSONNEL HAZARDS

A. Is there potential exposure of humans to chemical hazards, physical hazards, radioactive agents, or biohazardous agents during the course of animal experimentation?

Information needed:The committee is looking for information on anything used in the study that could be hazardous to lab or

vivarial staff personnel 1. Physical Describe:       Please complete Appendix B2. Chemical Describe:       Please complete Appendix B3. Radioactive Describe:       Please complete Appendix B 4. Biohazard Describe:       Please complete Appendix B

Does this biohazard require IBC approval?. YES - Proceed to Question B. below NO      

5. Recombinant DNA Describe:       Proceed to Question B. below B. Have you sought Institutional Biosafety Committee (IBC) review?

Yes, please provide the IBC#       Pending review- date of application to IBC:     

Page 10: Writing and Submitting an Animal Use Protocol Understanding the Process
Page 11: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION VI. NON-TECHNICAL SUMMARY

Using non technical language (lay) that a layperson with no scientific background would understand, provide a brief summary that describes the nature and purpose of the this study and its potential value to human or animal health the advancement of knowledge or the betterment of society. Do not use scientific jargon, acronyms or abbreviations and do not cut and paste from grant applications.

Information Needed:

The committee is made up of a diverse group of people and not all members are scientists. It is important that each member have a clear understanding of the nature of the proposal and the benefits of the study.

Page 12: Writing and Submitting an Animal Use Protocol Understanding the Process

Example of a Nontechnical summary - scientific terms defined

In general, an artery comprises of three layers: intima (faces lumen, inner most layer, covered by

endothelial cells, and are in contact with blood), media (middle layer, comprises mainly of smooth muscle

cells; SMC) and adventitia (outermost connective tissue). In a normal blood vessel, SMC are surrounded

by basement membranes, and prevent proliferation of SMCs. However, under pathological conditions,

proliferation of SMC leads to a thickened neointima (Neointima is an intima that forms in response to

injury). In about 30% of patients, this tissue remodeling process is so exuberant that it produces stenosis

(narrowing of the lumen) of the vessel and the development of related symptoms. The basement membrane

comprises many components, including elastin, collagens, and proteoglycans, whose expression and

deposition is tightly regulated by a delicate balance between matrix degrading metalloproteinases (MMP)

and tissue-inhibitors of metalloproteinases (TIMP). The purpose of this study is to examine the expression

levels of RECK (reversion-inducing cysteine-rich protein with kazal motifs), an MMP inhibitor and

EMMPRIN (extracellular matrix metalloproteinase inducer), an MMP inducer, in an animal model of

balloon catheter-injured carotid artery. The ultimate goal is to see its expression and regulation during the

course of the disease, and verify whether increasing RECK expression suppresses neointimal hyperplasia.

Page 13: Writing and Submitting an Animal Use Protocol Understanding the Process

Example of a nontechnical summary without scientific terms

Exposure to particular types of pathogenic Burkholderia sp. bacteria can result in infection

and disease. Currently, infectious disease caused by this particular class of bacteria is

emerging in parts of the world as a significant source of morbidity and mortality.

Development of new vaccines and therapeutics can greatly benefit in the future prevention

and treatment of disease. One of the essential steps in development and production of new

medical products is the development of animal models of disease. Animal models allow a

better understanding of the disease state and the role of natural and acquired immunity

during infection. Models also provide a test system for evaluation of newly-developed

treatments before clinical use. The objective of this research is to use the mouse as a small

animal model for the study of Burkholderia-related bacterial disease and vaccine testing.

Page 14: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION VII. COMPLETE DESCRIPTION

HYPOTHESES •This should be brief - one or two sentences that clearly explains the observation, phenomenon, or scientific problem that you are testing. •You can use scientific terminology in this section. If however there are terms that are used solely in your field of expertise it may be best to provide a brief explanation.

Example 1If the effect of biological sex on performance of the object-in-place task in rats is similar to the effect of biological sex on performance of the Silverman-Eals task in humans, we predict that female rats will outperform male rats. However, because ovarian steroids can affect performance on cognitive tasks, we predict that ovariectomized females that receive estradiol and progesterone replacement will outperform ovariectomized females treated with vehicle, as well as outperform gonadally-intact males.

Example 2Long term treatment with sodium nitrite has beneficial effects in attenuating the progression of experimental PH’.

Page 15: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION VII. COMPLETE DESCRIPTION

Information needed:• Concise description of the experimental course

of an animal from its ENTRY into the experiment to the ENDPOINT of the study.

• Chronological order is important• Provide a table

Page 16: Writing and Submitting an Animal Use Protocol Understanding the Process

Example of description utilizing written text

•Animal model: Sprague-Dawley rats, male, age 2 months, weight: ~200 g, will be purchased from Charles River Laboratories.

•Anesthesia: Isoflurane, 5% for induction and 2% for maintenance in oxygen. We will confirm that a surgical plane of anesthesia has been reached by testing pedal reflexes (by toe pinching).

•Balloon catheter injury: After one week of stabilization, hair on the thigh will be shaved, scrubbed with alcohol and sprayed with betadine. Bupivicaine will be used as a local anesthetic. After an incision in the thigh, the femoral artery is isolated, and a balloon catheter (Maverick® Over-The-Wire catheter (20 × 2.0 mm; Boston Scientific Corporation, Natick, MA, USA) will be inserted and advanced to the carotid under fluoroscopic guidance. The positioning of the catheter can be seen on the screen. THESE PROCEDURES HAVE BEEN FOLLOWED FOR SEVERAL YEARS and the co-investigator has extensive published experience. The balloon will be inflated and maintained at 4.0 atm for exactly 20 sec. The pressure will then be reduced to 2 atm for denuding the endothelium and the catheter will be dragged to the descending aorta. At this point, the catheter will be deflated totally and the pressure made negative. The catheter will then be gently withdrawn before tying the artery. The incision will be closed with Vicryl sutures and the animals will be allowed to recover before being returned to the vivarium. The animals will be under careful observation and concerns about the well being of the animal would be brought to the notice of the veterinarian.

•Euthanasia: Animals will be euthanized (SOP 3.5.2) on days 7 and 14 following the procedure. We chose these two time periods based on the assumption that suppression of RECK gene and protein expression may occur much before ECM degradation and SMC hyperplasia. •Tissue collection: Both injured and the contra-lateral carotid arteries (for comparison) will be harvested. •End points: •Histology for SMC hyperplasia, lumen size, and localization of RECK and EMMPRIN.•Expression levels of both RECK and EMMPRIN will be analyzed.

Page 17: Writing and Submitting an Animal Use Protocol Understanding the Process

Example of description utilizing written text

1. Subjects. Male and female adult Long-Evans rats (75 days of age) will be obtained from Harlan Sprague-Dawley, Inc., housed in pairs by sex, and maintained on reverse light-dark cycle (12:12, lights off at 07:00).

2. Ovariectomy. One week after arrival, females will be ovariectomized by a procedure routinely used in our laboratory in the past and approved under previous protocols. Males will undergo sham surgery. The procedures are conducted under aseptic conditions using sterile surgical drapes and swabs, and autoclaved instruments, sutures, and wound clips. Experimenters wear sterile surgical gloves, surgical masks, and laboratory coats. Rats are anesthetized by intraperitoneal injections of ketamine (100 mg/kg) and xylazine (7 mg/kg). Prior to surgery, the incision site on each flank is shaved and cleaned thoroughly with iodine-povidine solution. Following excision of the ovary, ovarian vessels are tied off with sterile suture, the muscle wall is closed with sterile suture, and the skin is closed with sterile wound clips. Body heat is maintained under heat lamps until consciousness is regained and animals are returned to vivarium. Ibuprofen (Children’s 100, 25 mg/kg) is added to drinking water for 2-3 days and rats are monitored regularly over several days. Post-surgical complications from this procedure are rare. Males will be anesthetized and bilateral flank incisions will be closed with suture and wound clips as described above.

 

3. Hormone Treatments. Beginning one week after surgery, females will be treated by intramuscular injections of estradiol benzoate (10 micrograms, 48 hr before cognitive testing) and progesterone (500 micrograms, 4-6 hr before cognitive testing), both delivered in 0.1 ml of sesame oil vehicle. Control females and males will receive parallel injections of 0.1 ml sesame oil at 48 and 5 hours before testing. Rats will receive these treatments each week prior to administration of cognitive tests.

 

4. Cognitive Testing. Rats will be evaluated on an object-in-place task described by Barker et al. (J. Neurosci. 27:2948, 2007). For this task, four different objects (e.g., can, bottles, bowls, cups) will be placed in the corners of a black Plexiglas open field (90 cm x 90 cm x 45cm). Each rat will be introduced into the open field, and the amount of time spent exploring the four objects will be recorded by DVD during a 5-minute information trial. Each rat then will be transferred to a holding cage for 5 minutes, 1 hour, or 2 hours before being re-introduced to the open field. During the retention trial, two of the original objects will be relocated to new positions in the open field. Time spent exploring each of the four objects will be recorded during a 5-minute retention trial. The open field and objects will be wiped cleaned with an ethanol solution and air-dried between each trial. Significantly increased time spent investigating the objects relocated to novel locations indicates memory for their original location. All rats will be tested at each of the three delay intervals on three weekly tests.

 

Page 18: Writing and Submitting an Animal Use Protocol Understanding the Process
Page 19: Writing and Submitting an Animal Use Protocol Understanding the Process

Group Name Group Description Number of Animals

Group 1 Sylvatic DENV serotype 2, strain PM33974 inoculated 3

Group 2 Human DENV serotype 2, strain NGC inoculated 1

Day Post Inoculation Group 1 (n=3) Group 2 (n=1)

-3

BLD-Clot (4.9 ml)BLD-CBC (1.2 ml)BLD-Chem (1.1 ml)

PE

BLD-Clot (4.9 ml)BLD-CBC (1.2 ml)

BLD-Chem (1.1 ml) PE

0INOC – Subcutaneous (DENV-2 PM33974,

5log10 pfu, 1 ml) PE

INOC – Subcutaneous (DENV-2 NGC, 5log10 pfu, 1 ml)

PE

1 BLD-Clot (2.2 ml) PE

BLD-Clot (2.2 ml) PE

2 BLD-Clot (2.2 ml) PE

BLD-Clot (2.2 ml) PE

3

BLD-CBC (1.2 ml)BLD-Chem (1.1 ml)BLD-Clot (1.1 ml)

PE

BLD-CBC (1.2 ml)BLD-Chem (1.1 ml)BLD-Clot (1.1 ml)

PE

Page 20: Writing and Submitting an Animal Use Protocol Understanding the Process
Page 21: Writing and Submitting an Animal Use Protocol Understanding the Process

C. STANDARD OPERATING PROCEDURES

Page 22: Writing and Submitting an Animal Use Protocol Understanding the Process

D. PROPOSED TREATMENTS

The list below contains some common drugs and doses and must be checked if they will be administered in this protocol.

Page 23: Writing and Submitting an Animal Use Protocol Understanding the Process

E. VETERINARY CARE

• Routine care is the most common choice• Special care- is only when veterinary

interaction is needed based on the study. This section is NOT for husbandry or management issues such as frequent cage changing.

Page 24: Writing and Submitting an Animal Use Protocol Understanding the Process

F. ADVERSE EFFECTS /CLINICAL ENDPOINTS

 Example Response:

In the event of post-surgical complications, consultation and treatment by the attending veterinarian are available. If any rat appears ungroomed or debilitated during the course of the experiment, the rat will be considered for euthanasia. If any rat discontinues drinking or eating during the course of the experiment, this discontinuation must be limited to less than 20% weight loss, and the rat will be considered for euthanasia. Animals are weighed one time one week after surgery and then every day during the food deprivation part of the study. If there is discomfort arising from surgery that cannot be alleviated (see below), animals will be considered for euthanasia. In addition, rats that show signs of distress in the water maze and could be at risk for drowning will not be allowed to continue in the experiment. If the water maze is the last experiment in the study, we will consider euthanasia. If the water maze is not the last experiment, rats will be allowed to continue other non-water learning tasks.

Page 25: Writing and Submitting an Animal Use Protocol Understanding the Process

F. ADVERSE EFFECTS /CLINICAL ENDPOINTS

Example Response:

Based on the current literature radiation of the lungs results in pneumonitis 6 – 12 weeks post-irradiation that progresses to fibrosis during weeks 16 – 38 post-irradiation (Fleckenstein et al. Temporal onset of hypoxia and oxidative stress after pulmonary irradiation. Int J Radiation Oncology Biol phys, 68:196, 2007). Breathing frequency is expected to increase approximately 6 weeks post irradiation but the overall health of the animals is not expected to be impaired during the course of our experiments. However the animals will be monitored daily and any that develop signs of distress, including ruffled fur, obvious lethargy, hunched posture, cachexia, cyanosis or labored breathing, will be removed from the study and immediately euthanized by exsanguination.

Page 26: Writing and Submitting an Animal Use Protocol Understanding the Process

G. ENDPOINTS

  You can choose more than one selection based on the study.

• The Policy of Humane Experimental Endpoints in Rodent Research is acceptable for this study.  

• The endpoints for this study are time based and noted on the Experimental Design Section VII.B. However, if an animal’s physical condition deteriorates the Policy of Humane Experimental Endpoints in Rodent Research is acceptable for this study.

• There is NO ENDPOINT to this study other than the approved study period and euthanasia is not required. However, if an animal’s physical condition deteriorates the Policy of Humane Experimental Endpoints in Rodent Research is acceptable for this study.

• I choose not to use the Policy of Humane Experimental Endpoints in Rodent Research - Please list the criteria to use to determine when euthanasia will be performed.  

Page 27: Writing and Submitting an Animal Use Protocol Understanding the Process

H. EUTHANASIA METHOD

Information needed:• Make sure to describe the euthanasia method• You may have more than one method• Justify any methods not consistent the the

AVMA Guidelines on Euthanasiawww.avma.org/issues/animal_welfare/ euthanasia.pdf 

Page 28: Writing and Submitting an Animal Use Protocol Understanding the Process

Example Response with more than one method

• CO2 euthanasia per SOP 3.5 by the Vivarium staff.

• Rats will be injected with an anesthetic combination of ketamine (100 mg/kg) and xylazine (5 mg/kg) prior to either intracardiac perfusion. Intracardiac perfusion is a standard laboratory procedure necessary for proper fixation of brain tissue that will analyzed by immnocytochemistry. After the induction of deep anesthesia, the rat will be placed under a fume hood and a chest incision will be made to expose the pericardial cavity. An 18-gauge needle will be inserted into the left ventricle through which 150 ml of heparinized PBS will be delivered to clear the brain of blood, followed by 250 ml of a 4% paraformaldehyde solution. A small incision in the right atrium will allow exit of the perfusate from the body. Following perfusion, the brain will be removed, cryoprotected, frozen, and stored at -70 C prior to sectioning for immunocytochemical analysis.

• Rats will be anesthetized with isoflurane inhalation by placing them gently

on a raised platform in a large Bell jar that is saturated with isoflurane vapors and will be monitored till completely anesthetized. They will be then rapidly decapitated and brains removed.

Page 29: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION VIII. ANIMAL USE JUSTIFICATION

A. RATIONALE FOR ANIMAL USE

Example ResponseAt the present time, non‑animal alternatives are not available

to answer fundamental questions about the neuronal mechanisms that cause learning-related changes in behavior. To forge links between neuronal function, memory, and behavioral output, it is important to identify not only learning-related changes at the neuronal level but to determine which of those changes are related to functional and behavioral consequences. To accomplish that goal, studies require measurement of neuronal markers and behavior, both, and thus the use of intact, behaving animals.

Page 30: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION VIII. ANIMAL USE JUSTIFICATION

B. APPROPRIATENESS OF THE SPECIES SELECTED- While question A justified using a live animal, this question should pertain to the species used.

Example Response:

SD rat has been extensively used to study the mechanisms of intimal hyperplasia. We also have extensive experience with the rat model, and have necessary surgical skills and instruments. Mice have also been used to study intimal hyperplasia, but are technically challenging and the mortality is much higher.

Page 31: Writing and Submitting an Animal Use Protocol Understanding the Process

C. ANIMAL NUMBER JUSTIFICATION

Citation of previous research

Provide enough information to indicate that the previous research is similar enough in concept and methodology to make it reasonable to use similar sample sizes in the proposed research project.

Example response:

We and others have shown that statistical significance can be best evaluated using a group number of between 6 and 8 for microdialysis studies (Inglis et al, Verrico et al, Ichikawa et al). Each of these studies was similar in that probes were implanted into a region of brain such as the prefrontal cortex, and neurotransmitter release evaluated in perfusate from the dialysis probes. Verrico et al. and Ichikawa et al. employed similar drug studies, but in different regions of the brain, suggesting that these studies are feasible with group numbers given. In our extensive experience, numbers required are greater than the number of animals cited, due to possible misplacement of microdialysis probes (caused by deflection of the probe tip when it encounters, for example, a blood vessel), blockage or damage to probe. Thus, we propose to use an n of 10 per microdialysis group. (6 groups = 60 animals).

Refs cited: •Inglis et al., 1994. Enhanced acetylcholine release in hippocampus and cortex during the anticipation and consumption of a palatable meal. Neuroscience, 62:1049-1056. •Verrico et al., 2003. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse, 48:178-83. •Ichikawa et al., 2002. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology  

 

Page 32: Writing and Submitting an Animal Use Protocol Understanding the Process

Statistical analysis- if numbers are chosen with the intent of obtaining statistically significant differences, the most objective tool is usually a power analysis to determine sample size. When groups are compared, the goal of conducting a power analysis is to determine the appropriate number of animals per group to ensure detection of a significant difference.

Example of response:

First, we can harvest 4-6 viable segments of the middle or posterior cerebral arteries which do not have significant side branches. The side branches prevent us from pressurizing the segments and thus they are not usable for our studies. Although we could also harvest segments of the posterior cerebral arteries, we prefer to focus on only one cerebral artery because of well documented variations in responsiveness. Second, we will only use one protocol per arterial segment to avoid “carry over” of effects unless specifically desired. Third, we will sample arteries for western blotting at different times following application of drugs to determine the time course of responses. Fourth, we find that an average sample size of 10 is appropriate for statistical validity for most types of measurements. Fifth, not all possible experimental manipulations will be done. If some experiments initially appear to be nonproductive, or less important than other protocols, we will go on to the next set of experiments. Based upon previous studies, a sample size of 10 for the vascular studies is needed to show a group differences. This number is based upon:

Vascular studies

1. α=.05

2. power=.80

3. δ=13

4. within group SD=11

5. m=1.0

Page 33: Writing and Submitting an Animal Use Protocol Understanding the Process

Pilot study•Main outcome measure being evaluated (e.g. reduction in tumor size)•The definition of success (e.g., a 50% reduction in tumor size in 3 animals) that would indicate that the study should be followed up by a full study.

Example Response:This is a pilot study and we will use a total of 4 animals. Two will be used to determine the mechanisms of physiological high monocyte turnover. The other two will be used to determine when the monocyte turnover rate returns to that observed in adults. Outcome will be measured by the turnover rate of monocytes, macrophages and dendritic cells with BrdU injection and flow cytometric analysis

Page 34: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION IX. ALTERNATIVES TO PAINFUL AND DISTRESSFUL PROCEDURES

You must consider alternatives to procedures that may cause more than momentary or slight pain or distress.

Alternatives are defined as new methods that:•refine existing usage by minimizing animals’ distress such as the use of analgesics, •reduce animal usage such as the use of certain experimental designs, or •replace whole animal tests with other procedures such as the use of in vitro analyses.

Page 35: Writing and Submitting an Animal Use Protocol Understanding the Process

• When searching for literature on refinement procedures the subject matter frequently relates to ANIMAL WELFARE or to ANIMAL BEHAVIOUR.

• With reduction procedures, the methodology may often relate to MATHEMATICAL AND STATISTICAL PHENOMENA concerned with the design and validation of experiments.

• When considering replacement options, the relevant literature often describes work emphasizing methodology (METHODS, PROCEDURES and TECHNIQUES) and the use of human tissue, lower organisms or animal tissue instead of whole animals (TYPES OF STUDY, ORGANISMS).

Page 36: Writing and Submitting an Animal Use Protocol Understanding the Process

Example Literature Search

PubMed search yielded one item suggesting an alternative. Sci Am. 1997 Feb;276(2):80-2. The authors of the article cite selected instances in the research use of animals that led to erroneous conclusions. For example, they point out that rodent inhalation studies in the 1960s indicated that cigarette smoke did not cause lung cancer. Instead of animal models the authors advocate the use of epidemiological studies. However, they did not cite more recent studies that demonstrated an association between lung cancer in rodents and exposure to tobacco smoke.

Database Used Date of search Period covered by search

Keywords used Number of relevant references

Were alternatives found

Pubmed 06/08/10 1966-2010 animal testing alternatives AND lung cancer

6 1

Pubmed 06/08/10 1966-2010 animal testing alternatives AND cigarette smoke AND asbestos

0 0

Page 37: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION X. ENVIRONMENTAL ENHANCEMENT-Housing

The housing requirements are dependent on the species and we

follow the Guide.

Single housing for any species must be justified

Example of justification for single housing:Rats may be housed in groups, unless one of the following conditions occurs.

First, aggressive behaviors may be displayed by group-housed males, and this

aggression can lead to injuries. Second, some of the rats will be food-restricted for one

week, a procedure that may promote additional aggression between cage mates. Third,

rats will undergo surgery, and group-housed animals may disturb incision sites on cage

mates. Under these conditions, the animals may need to be housed in single cages for a

brief period of time. The decision to house the animals in group versus single housing

will be made in consultation between the investigators and the Vivarium staff

Page 38: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION X. ENVIRONMENTAL ENHANCEMENT-Enrichment

3 levels of enrichment 1.Standard Enrichment 2.Specific Enrichment 3.Restricted Enrichment – this one must be justified

Example of Justification for restricted enrichment:Previous findings from our laboratory indicate that the effects of ovariansteroids on cognitive performance are affected dramatically when rats arehoused in enriched conditions, masking the effects of hormone treatments oncognitive performance (Daniel et al., Physiol Behav. 66:11, 1999). If femalesin the current study are housed under enriched conditions, it will not bepossible to study the effects of ovarian steroids on cognitive performance.

Page 39: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION XI. PERSONNEL

Information needed:•The committee only needs personnel that will have direct contact with animals. •We must know their role i.e. injections, surgery etc. and you must list the training or experience for that specific role.

Example:

NAME/ TITLE SPECIFIC ROLE ON PROJECT TRAINING

Person A - PI All aspects 12+ Years experience with murine models

Person B- Post doc Inoculations; anesthesia; tissue collection; euthanasia

Will be supervised by the PI and completed rodent wet lab training

Person C- lab staff Inoculations; anesthesia; tissue collection; euthanasia

Will be supervised by the PI and completed rodent wet lab training

Page 40: Writing and Submitting an Animal Use Protocol Understanding the Process

SECTION XII. FACILITIES

List any room that is not part of the vivarium where a LIVEanimal is brought for experimentation or euthanasia. You need

to state what procedures are being done in the lab.

Example:

BUILDING ROOM NUMBER USE

TMC 7620 Injections, euthanasia

Page 41: Writing and Submitting an Animal Use Protocol Understanding the Process

Protocol Submission Process

• Protocols are due on the first of the month ( next business day if first falls on holiday or weekend)

• If possible an administrative review is done. This review is done to try to present to the IACUC the most complete protocol

• Protocols missing responses are sent back to the PI and must be revised one week before the meeting

• Meetings are held 2nd week (UT) and 3rd week (DT)

• After the IACUC meeting, each protocol receives a disposition and a letter is sent to the PI with the disposition, comments or questions. This occurs within 1-2 weeks after the meeting.

Page 42: Writing and Submitting an Animal Use Protocol Understanding the Process

Disposition Explanation

• Approved as Submitted – The PI has clearly explained the animal procedures, included all justifications and answered all questions

• Approved with Administrative Notations - These are minor changes that the IACUC Office will review. This protocol does not need to go back to the committee or designated reviewer for review

• Modifications to Secure Approval (~90%) – The committee has questions on the study. These can range from one question to over 10 questions. The revised protocol is reviewed by one or more designated reviewers.

• Deferred – The committee does not have a clear understanding of what the PI is proposing and needs to review a revised version as a full committee.

• Withhold approval – The committee rarely ever renders this disposition. The committee would have to agree that the research should not be conducted and this could be due to a variety of reasons

Page 43: Writing and Submitting an Animal Use Protocol Understanding the Process

Review Outcomes

Page 44: Writing and Submitting an Animal Use Protocol Understanding the Process

The IACUC OfficeTidewater

http://tulane.edu/asvpr/iacuc/

504-988-6868 (office)

504-988-1445 (fax)

504-481-9684 (cell)

985-871-6636 (TNPRC Thursday)

[email protected]